Monday morning’s trading session was not a pleasant one for DexCom (DXCM) or its investors. Shares of the medical device manufacturing company fell 8% by 12PM EST with no signs of slowing down. But what happened to cause this slip? It wasn’t necessarily anything DexCom did or didn’t do. Rather, close competitor Abbott Laboratories [...]
As Pfizer’s sales continue to struggle, they’ve turned to acquisitions as a means of making up for lost revenue. And one company they have their eye on is Seagen - a cancer drugmaker with a market cap of roughly $30 billion. Last year, Seagen was rumored to be acquired by Merck. This deal could [...]
As of 11 AM EST Friday morning, Nuvalent has gained over 50% on its share price. The stock topped out at around $38/share (a 75% gain) but has started to trend back downwards and currently sits at $33/share. What happened to cause this spike? The company creates precisely targeted cancer treatments designed to [...]
Yesterday, we discussed how Crispr stock enjoyed a short-lived jump ahead of seeking FDA approval for their gene therapy drug. But today, we’re here to talk about a drug company that has experienced a much larger spike as a result of positive news: Biogen. Biogen is engaged in discovering, developing, and delivering therapies for [...]
While many stocks are moving downwards this morning, one stock has made a nice 5% jump since the market opened - and that’s Crispr. The company is engaged in the development of transformative drugs based on gene therapy. And news just released that they are finally on the path to seeking FDA approval for [...]
